Please login to the form below

Sun Pharmaceutical

This page shows the latest Sun Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Sun Pharmaceutical’s Ilumya (tildrakizumab) in recent years.

Teva among generic drugmakers hoping to settle US antitrust probe

As well as Teva, India-domiciled drugmaker Sun Pharmaceutical has also been in talks with the DoJ to settle the allegations.
Sun Pharma passes milestone with novel psoriasis drug approval

India’s largest drugmaker Sun Pharmaceutical has picked up its first FDA approval for a novel drug, getting the nod for plaque psoriasis therapy Ilumya. ... Ilumya isn’t entirely home-grown, as Sun Pharma licensed the interleukin-23 (IL-23) inhibitor
Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects. Merck &Co and India's Sun Pharmaceutical Industries have agreed to dissolve a joint venture set up in 2011 to develop and ... Sun acquired global rights to tildrakizumab (MK-3222)
Daiichi Sankyo offloads stake in India's Sun Pharma

Daiichi Sankyo has found a buyer for its $3.6bn holding in India's Sun Pharmaceutical almost immediately after putting the stake up for sale. ... The merger of Sun and Ranbaxy created the world's fifth largest speciality generic pharmaceutical company
Ranbaxy hit with EU import ban on antibiotic

Ranbaxy is the subject of $4bn takeover bid from fellow Indian firm Sun Pharmaceutical that would offer its current majority shareholder Daiichi Sankyo a partial exit.

More from news
Approximately 2 fully matching, plus 35 partially matching documents found.

Deal Watch September 2016

India's Sun Pharmaceutical has partnered with Mitsubishi Tanabe Pharma to distribute and market 14 prescription drugs in Japan that Sun recently acquired from Novartis. ... No financial terms were disclosed. Genentech signed an exclusive licence [global
Pharma deals during April 2014

April also saw Sun Pharmaceutical Industries relieving Daiichi Sankyo (63.9% owner) of the troubled Ranbaxy Laboratories to create India's largest pharma company, leading in 13 speciality segments, with estimated ... is rumoured that a solution will be
Deal Watch table for June 2013

Pfizer (Wyeth) Takeda / Teva Sun Pharmaceutical. Patent settlement. Infringement of Protonix patent. ... 39.5. BioLineRx / Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ)†. Collaboration and licence.
Pharma deals during June 2013

Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead ... damages (Teva $1.6bn and Sun Pharma $550m); Pfizer

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...